Pancreatic Cancer Research

ResearcherFriedrich-Alexander-Universität Erlangen-NürnbergActive in the last 2 years

Frederik J. Hansen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-7452-1189; OpenAlex author ID A5029297139. Sources: OpenAlex.

Their work

Papers
7 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
20
Papers, trials and grants by year

2023: 1 paper · 2024: 2 papers · 2025: 3 papers · 2026: 1 paper

Papers 7

  1. Immune Cell-Specific and Isoform-Selective Regulation of CD44 in Pancreatic Ductal Adenocarcinoma Links Lymph Node Variant Loss and Exosomal CD44 to Clinical O… Co-author DOI 10.3390/cells15050411↗
  2. A sex dependent association between the history of autoimmune disease and the development of pancreatic cancer: a case-control study of 32,640 patients. First author DOI 10.3389/fonc.2025.1613787↗
  3. Exosomal CD40, CD25, and Serum CA19-9 as Combinatory Novel Liquid Biopsy Biomarker for the Diagnosis and Prognosis of Patients with Pancreatic Ductal Adenocarc… Co-author DOI 10.3390/ijms26041500↗
  4. Increased Herpesvirus Entry Mediator Expression on Circulating Monocytes and Subsets Predicts Poor Outcomes in Pancreatic Ductal Adenocarcinoma Patients. Co-author DOI 10.3390/ijms26072875↗
  5. CD71 expressing circulating neutrophils serve as a novel prognostic biomarker for metastatic spread and reduced outcome in pancreatic ductal adenocarcinoma pat… Co-author DOI 10.1038/s41598-024-70916-3↗
  6. Exosomal ROR1 in peritoneal fluid identifies peritoneal disseminated PDAC and is associated with poor survival. Co-author DOI 10.3389/fimmu.2024.1253072↗
  7. Circulating Monocytes Serve as Novel Prognostic Biomarker in Pancreatic Ductal Adenocarcinoma Patients. Co-author DOI 10.3390/cancers15020363↗

Closest collaborators

The 20 strongest of 20 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Anke Mittelstädt · 6 shared papers, 2023–2026 · strength 1.08
  2. Georg F. Weber · 6 shared papers, 2023–2026 · strength 1.08
  3. Paul David · 6 shared papers, 2023–2026 · strength 1.08
  4. Christian Krautz · 5 shared papers, 2023–2026 · strength 0.87
  5. Robert Grützmann · 5 shared papers, 2023–2026 · strength 0.87
  6. Maximilian Brunner · 5 shared papers, 2023–2026 · strength 0.87
  7. Alara Karabiber · 4 shared papers, 2024–2026 · strength 0.79
  8. Isabelle Kuchenreuther · 3 shared papers, 2024–2026 · strength 0.57
  9. Lisa-Sophie Arnold · 2 shared papers, 2024–2025 · strength 0.35
  10. Karel Kostev · 1 shared paper, 2025 · strength 0.33
  11. Sven Heiko Loosen · 1 shared paper, 2025 · strength 0.33
  12. Christoph Roderburg · 1 shared paper, 2025 · strength 0.33
  13. Tom Luedde · 1 shared paper, 2025 · strength 0.33
  14. Anne Jacobsen · 2 shared papers, 2024 · strength 0.30
  15. Yong Jian Zhou · 1 shared paper, 2026 · strength 0.22
  16. Timur Buniatov · 1 shared paper, 2024 · strength 0.15
  17. Sabine Semrau · 1 shared paper, 2024 · strength 0.15
  18. Yurdagül Zopf · 1 shared paper, 2024 · strength 0.15
  19. Axel Denz · 1 shared paper, 2024 · strength 0.15
  20. Danilo Hackner · 1 shared paper, 2024 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.